Gilead Sciences | GILD - Operating Profit

Stock Price
144.41
Daily Change
-0.80 -0.55%
Monthly
-5.45%
Yearly
31.01%
Q1 Forecast
140.61

Gilead Sciences reported $2.96B in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Incyte USD 383.88M 47.43M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025